Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Oxford Pharmascience Group plc
DescriptionIonized formulation of 400 mg ibuprofen delivered via OXPzero technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationPain
Indication DetailsTreat conditions requiring the chronic use of NSAIDs with reduced gastrointestinal side effects
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today